Dr Simon Calaminus S.Calaminus@hull.ac.uk
Platelet cAMP signalling controls thrombosis through enhanced embolisation
People Involved
Project Description
The activation of protein kinase A (PKA) by prostacyclin inhibits platelet activation and therefore modulates arterial thrombosis. However, the role of PKA in controlling the stability of pre-existing thrombi is unclear. The stability of thrombi is reliant on the correct activation of the platelet actin cytoskeleton by a number of RhoGTPases. We have shown recently that PKA inhibits the activation of the small RhoGTPase RhoA, which blocks actin remodelling. We now have preliminary data that suggest PKA can reverse stress fibre formation, which is required for thrombus stabilisation. We hypothesise that PKA signaling can reverse actin restructuring in thrombus localised platelets, reducing thrombus structural integrity and promoting embolisation as a mechanism to control thrombus size. Data from this study will reveal new insights into the role of PKA signaling in platelets and demonstrate that PKA plays a dual role both in platelet inhibition prior to thrombus formation, but also in limiting the overall size of a thrombus by modulation of the platelet cytoskeleton.
| Type of Project | Project |
|---|---|
| Status | Project Complete |
| Funder(s) | British Heart Foundation |
| Value | £106,467.00 |
| Project Dates | Oct 1, 2015 - Sep 30, 2018 |
You might also like
ThrombiGlow: ‘Smart’ Multimodal Platelet Specific ‘Theranostic’ Drug Delivery Imaging Feb 1, 2017 - Jan 31, 2020
Cardiovascular diseases (CVD) including heart attacks and strokes constitute the leading cause of mortality in the UK. The pathology underlying CVD is called atherothrombosis and is a complex, multi-cellular-inflammatory disorder. Central to this is...
Read More about ThrombiGlow: ‘Smart’ Multimodal Platelet Specific ‘Theranostic’ Drug Delivery Imaging.
Is zinc a critical modulator of cyclic nucleotide signalling? Oct 1, 2019 - Dec 31, 2022
inc (Zn2+) deficiency is present in multiple conditions from obesity to cancer. However importantly Zn2+ deficiency can lead to a bleeding phenotype.In this proposal we investigate how Zn2+ is important for the control of platelet cyclic nucleotide...
Read More about Is zinc a critical modulator of cyclic nucleotide signalling?.
Effect of hypoxia on prostacyclin-mediated inhibition of platelet function Jan 1, 2023 - Dec 31, 2025
Tissue hypoxia occurs in multiple cardiovascular and pulmonary conditions that have platelet activation or hyperreactivity, including myocardial infarction, stroke, chronic obstructive pulmonary disease (COPD) and sleep apnoea. However, knowledge on...
Read More about Effect of hypoxia on prostacyclin-mediated inhibition of platelet function.
TARGETING THE MYOSIN LIGHT CHAIN PHOSPHATASE WITH PEPTIDE DISRUPTORS: A NOVEL ANTIPLATELET THERAPEUTIC APPROACH Jul 3, 2023 - Jul 2, 2026
Platelet activation and thrombus formation play key roles in the pathogenesis of ischaemic cardiovascular diseases, one of the major causes of death in the UK. Many antiplatelet agents have been developed to manage these conditions; however, they are...
Read More about TARGETING THE MYOSIN LIGHT CHAIN PHOSPHATASE WITH PEPTIDE DISRUPTORS: A NOVEL ANTIPLATELET THERAPEUTIC APPROACH.